Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.39 |
| ▸ | MDM4 | O15151 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PRKCB | P05771 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | PRKCH | P24723 | 1/20 | 0.38 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204559 | 0.90 | MEN1 (0.44) | TP53GPR84ALOX5PRKCBPRKCA | |
| SCHEMBL2204661 | 0.84 | SIRT2 (0.44) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL2207008 | 0.77 | GAA (0.44) | RAB9AMEN1KMT2AALDH1A1NR4A2 | |
| SCHEMBL2204923 | 0.77 | S100A4 (0.45) | GSK3BGPR84CYP1A2 | |
| SCHEMBL2200948 | 0.75 | GPR84 (0.40) | GPR84PRKCBPRKCAPRKCHPRKCQ | |
| SCHEMBL2201341 | 0.74 | PDE4B (0.47) | GPR84NPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL2202690 | 0.74 | MAPT (0.45) | — | |
| SCHEMBL2204921 | 0.72 | MAP2 (0.45) | GSK3BMEN1KMT2AALDH1A1GSK3A | |
| SCHEMBL7640758 | 0.71 | MAOB (0.43) | GSK3BMDM2TP53NPC1RAB9A | |
| SCHEMBL15477955 | 0.70 | IMPDH2 (0.58) | DYRK1AGSK3BMDM2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981912-B2 | Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100016389-A1 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH (US) | 2010-01-21 | — | — | US | disclosed |
| US-7601749-B2 | Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1805171-A4 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH CORP (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20090111867-A1 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH (US) | 2009-04-30 | — | — | US | disclosed |
| US-7476667-B2 | Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH (US) | 2009-01-13 | — | — | US | disclosed |
| US-20080255100-A1 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH (US) | 2008-10-16 | — | — | US | disclosed |
| US-7405215-B2 | Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1805171-A2 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | Athersys, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20060100425-A1 | Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | ATHERSYS, INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006034419-A2 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | ATHERSYS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100425-A1 | Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | PTGDR2, TBXA2R, HCAR2 | DYRK1A 1241/4885GSK3B 2899/4885MDM2 2037/4885 |
| US-20080255100-A1 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | PTGDR2, TBXA2R, HCAR2 | DYRK1A 1241/4885GSK3B 2899/4885MDM2 2037/4885 |
| US-20100016389-A1 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | PTGDR2, TBXA2R, HCAR2 | DYRK1A 1241/4885GSK3B 2899/4885MDM2 2037/4885 |
| US-20090111867-A1 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | PTGDR2, TBXA2R, HCAR2 | DYRK1A 1241/4885GSK3B 2899/4885MDM2 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.